Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients

Therapeutic Drug Monitoring

Volumn 29, Issue 6, 2007, Pages 773-780

  Saracino, Maria Addolorata ^a   Koukopoulos, Athanasio ^b   Sani, Gabriele ^c   Amore, Mario ^d   Raggi, Maria Augusta ^a,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Centro Lucio Bini   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e Department of Pharmaceutical Sciences ^*  (Italy)

Author keywords

Lamotrigine; Liquid chromatography; Olanzapine; Plasma samples; Solid phase extraction; Therapeutic drug monitoring

Indexed keywords

DRUG METABOLITE; LAMOTRIGINE; NOROLANZAPINE; OLANZAPINE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BIPOLAR DISORDER; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; SOLID PHASE EXTRACTION;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MOLECULAR STRUCTURE; TRIAZINES;

EID: 36549046650     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31815bde43     Document Type: Article

References (28)

1. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press; 1990.
2. Soares JC, Mann JJ. The anatomy of mood disorders-review of structural neuroimaging studies. Biol Psychiat. 1997;41:86-106.
3. Koukopoulos A, Sani G, Koukopoulos AE, et al. Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. J Affect Disord. 2003;73:75-85.
4. Sachs GS, Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry. 2000;48:573-581.
5. Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry. 2000;8:126-140.
6. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs. 2006;20:29-42.
7. Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness and treatment options. Bipolar Disord. 2003;5:85-97.
8. Bowden CL. Treatment options for bipolar depression. J Clin Psychiatry. 2005;66:3-6.
9. Raggi MA. Therapeutic drug monitoring: chemical-clinical correlations of atypical antipsychotic drugs. Curr Med Chem. 2002;9:1397-1409.
10. Sweetman SC. Martindale: The Complete Drug Reference, ed 34. London: Pharmaceutical Press; 2005:710-711.
11. Raggi MA, Mandrioli R, Pucci V, et al. Advances in therapeutic drug monitoring of atypical antipsychotic drugs. Med Chem Rev. 2004;1:299-316.
12. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit. 1997;19:252-260.
13. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia. 1996;37:4-11.
14. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology. 1999;53:53-67.
15. Ramsey RE, Pellock JM, Garnett WR, et al. Pharmacokinetic and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res. 1991;10:191-200.
16. D'Arrigo C, Migliardi G, Santoro V, et al. determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit. 2006;28:388-393.
17. Jasinska A, Starczewska B, Polkowska M, et al. Solid phase extraction of olanzapine with reverse phase sorbents prior to UV and HPLC analysis. Anal Lett. 2005;38:815-824.
18. Nirogi RVS, Kandikere VN, Shukla M, et al. Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of Olanzapine in human plasma. J Pharmaceut Biomed. 2006;41:935-942.
19. Theisen FM, Haberhausen M, Schulz E, et al. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit. 2006;28:750-759.
20. Ulrich S. Assay of olanzapine in human plasma by a rapid and sensitive gas chromatography-nitrogen phosphorus selective detection (GC-NPD) method: validation and comparison with high-performance liquid chromatography- coulometric detection. Ther Drug Monit. 2005;27:463-468.
21. Beck O, Oehman I, Nordgren HK. Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry. Ther Drug Monit. 2006;28:603-607.
22. Cheng CL, Chou CH, Hu OY. Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. J Chromatogr B. 2005;817:199-206.
23. Saracino MA, Bugamelli F, Conti M, et al. Rapid HPLC analysis of the antiepileptic agent Lamotrigine and its metabolites in human plasma. J Sep Sci. 2007;30:2249-2255.
24. Pucci V, Raggi MA. Analysis of antiepileptic drugs in biological fluids by means of electrokinetic chromatography. Electrophoresis. 2005;26:767-782.
25. Pucci V, Bugamelli F, Baccini C, et al. Analysis of lamotrigine and its metabolites in human plasma and urine by micellar electrokinetic capillary chromatography. Electrophoresis. 2005;26:935-942.
26. United States Pharmacopeia. ed 28. Rockville MD: United States Pharmacopeial Convention; 2005:2748-2751.
27. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
28. Sabbioni C, Saracino MA, Mandrioli R, et al. Rapid analysis of olanzapine and desmethylolanzapine in human plasma using high-performance liquid chromatography with coulometric detection. Anal Chim Acta. 2004;516:111-117.